rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AMPH
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Is Amphastar Pharmaceuticals (AMPH) Fully Priced After Strong Q3 Earnings And Q4 Guidance?
      Nov 13Yahoo FinanceAMPH
      Should Earnings Beat Require Action From Amphastar Pharmaceuticals (AMPH) Investors?

      Amphastar Pharmaceuticals reported third quarter 2026 revenue of US$207.61 million and net income of US$37.76 million, with adjusted earnings per share and sales both coming in ahead of consensus expectations. Record contributions from BAQSIMI and Primatene Mist, together with expanded authorization for the share repurchase program, highlighted management’s focus on higher margin products and capital return. This article examines how Amphastar Pharmaceuticals’ investment narrative is...

      Nov 7Yahoo FinanceAMPH
      Amphastar Pharmaceuticals stock hits 52-week high at $30.34
      Nov 6Investing.comAMPH
      Amphastar Pharmaceuticals Inc (AMPH) Q3 2026 Earnings Call Highlights: Record Revenue of $207. ...
      Nov 6Yahoo FinanceAMPH
      Amphastar Pharmaceuticals Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceAMPH
      Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
      Nov 5Yahoo FinanceAMPH
      Amphastar Pharmaceuticals (NASDAQ:AMPH) reports bullish Q3 2026, stock soars
      Nov 5Yahoo FinanceAMPH
      Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates

      Amphastar (AMPH) delivered earnings and revenue surprises of +46.15% and +6.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 5Yahoo FinanceAMPH
      Amphastar: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceAMPH
      Amphastar Pharmaceuticals earnings beat by $0.28, revenue topped estimates
      Nov 5Investing.comAMPH
      Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
      Oct 29Yahoo FinanceAMPH
      Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026
      Oct 29Yahoo FinanceAMPH
      Amphastar Pharmaceuticals (AMPH) Stock Looks About Right After A 42% Slide
      Oct 17Yahoo FinanceAMPH
      Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?

      Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

      Oct 6Yahoo FinanceAMPH
      Amphastar: 2 Years Since My Last Hold Call, I Remain On Sidelines (NASDAQ:AMPH)

      Amphastar is rated a Hold, and shares have dropped over 40%, now trading at ~$26.5 with a $1.1bn market cap. Read more on AMPH stock here.

      Sep 30Seeking AlphaAMPH
      Amphastar CFO William Peters sells $103,475 in stock
      Sep 23Investing.comAMPH
      Amphastar Pharmaceuticals (NASDAQ:AMPH): Strongest Q2 Results from the Generic Pharmaceuticals Group

      Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q2 generic pharmaceuticals earnings season.

      Sep 17Yahoo FinanceAMPH
      Amphastar’s senior EVP Rong Zhou sells $239,404 in stock
      Sep 17Investing.comAMPH
      Amphastar at Wells Fargo conference: growth hinges on baqsimi, pipeline
      Sep 8Investing.comAMPHWFC
      Amphastar Pharmaceuticals (AMPH) Rebounds In Focus, Is It Slightly Overvalued?

      Recent Price Moves Put Amphastar Pharmaceuticals in Focus Amphastar Pharmaceuticals (AMPH) has drawn fresh attention after recent share price swings, with the stock closing at $23.18 and showing mixed performance over the past week, month, past 3 months, and year. Short term, Amphastar Pharmaceuticals has seen momentum build, with a 30-day share price return of 11.55% and a 90-day share price return of 19.55%. Yet the 1-year total shareholder return is down 21.21%, pointing to a recovery that...

      Sep 6Yahoo FinanceAMPH
      Amphastar Pharmaceuticals (AMPH) Stock Looks Cheap With Earnings Doing The Heavy Lifting

      Amphastar Pharmaceuticals stock presents a tricky mix for investors, with a steep 3 year share price decline set against valuation checks that now lean cheap on traditional multiples. Over the past 3 years the share price has fallen about 53.6%, which leaves current holders facing a deep drawdown and raises the question of whether the stock has been pushed too far down. Future expectations for Amphastar Pharmaceuticals around the durability of its product portfolio and its ability to convert...

      Sep 5Yahoo FinanceAMPH
      Amphastar senior EVP Rong Zhou sells $75,305 in stock
      Sep 4Investing.comAMPH
      Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris

      Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.

      Aug 31Yahoo FinanceAMPHVTRS

      This is the newest page. Registered accounts read further back.